Testing pharmacological strategies to upregulate AKIP1 or deliver AKIP1 mimetics in disease models could offer promising avenues for treating oxidative-stress-related conditions, such as cardiovascular diseases, neurodegenerative disorders, and organ damage from ischemia–reperfusion injury. The gene discussed is AKIP1; the disease is cardiovascular disorder.